1. Home
  2. MLTX
  3. MLTX News

Latest MoonLake Immunotherapeutics (MLTX) News on September 18, 2025

Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX)
MLTX

Insider Monkey

8 days ago

Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX)

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
MLTX

Zacks

3 months ago

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

MLTX

MT Newswires

3 months ago

Update: Market Chatter: Merck Held Talks to Buy MoonLake for Over $3 Billion; MoonLake Shares Rise

Constellation and Meta, Merck, Snowflake: Trending Tickers
MLTX

Yahoo Finance Video

3 months ago

Constellation and Meta, Merck, Snowflake: Trending Tickers

MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid
MLTX

Investor's Business Daily

3 months ago

MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid

MLTX

MT Newswires

3 months ago

Market Chatter: Merck Held Talks to Buy MoonLake for Over $3 Billion; MoonLake Shares Rise Pre-Bell

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report
MLTX

Benzinga

3 months ago

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports
MLTX

Reuters

3 months ago

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

MLTX

Newsfile

4 months ago

Sienna Resources Inc. Announces Private Placement

MLTX

Energy Global

4 months ago

European Energy completes sale of Polish wind portfolio to Enea Group

MLTX

Newsfile

4 months ago

Carbone Restaurant Group is a GOLD Sponsor at the Centurion One Capital 6th Annual LA Summit

MLTX

Newsfile

4 months ago

Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

First Foundation Bank review (2025): Personal and business banking with competitive online rates
MLTX

Yahoo Personal Finance

4 months ago

First Foundation Bank review (2025): Personal and business banking with competitive online rates

MLTX

Investing.com

4 months ago

Airbnb shares dip as Truist cuts stock to Sell on weak summer trends, valuation

Report: Slower economy doesn't dim downtown Austin's dynamism
MLTX

Austin American-Statesman

4 months ago

Report: Slower economy doesn't dim downtown Austin's dynamism

Nvidia (NVDA) Gets Wall Street Boost on Strong Q1 Results and Upbeat Guidance
MLTX

GuruFocus.com

4 months ago

Nvidia (NVDA) Gets Wall Street Boost on Strong Q1 Results and Upbeat Guidance

H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT
MLTX

Insider Monkey

4 months ago

H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT

MLTX

MT Newswires

4 months ago

Wolfe Research Upgrades MoonLake Immunotherapeutics to Outperform From Peer Perform

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet
MLTX

Zacks

4 months ago

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

MLTX

MT Newswires

4 months ago

Wedbush Adjusts Price Target on MoonLake Immunotherapeutics to $80 From $78, Maintains Outperform Rating

MLTX

MT Newswires

4 months ago

MoonLake Immunotherapeutics Q1 Loss Widens

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
MLTX

GlobeNewswire

4 months ago

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
MLTX

GlobeNewswire

5 months ago

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
MLTX

Insider Monkey

5 months ago

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

MLTX

MT Newswires

5 months ago

MoonLake Obtains $500 Million Facility From Hercules Capital

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
MLTX

GlobeNewswire

5 months ago

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

MLTX

MT Newswires

6 months ago

Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target

MLTX

MT Newswires

6 months ago

RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target

MLTX

MT Newswires

7 months ago

MoonLake Immunotherapeutics Q4 Loss Widens

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
MLTX

GlobeNewswire

7 months ago

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?
MLTX

Insider Monkey

7 months ago

Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?

MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts
MLTX

Insider Monkey

7 months ago

MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts

MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now
MLTX

Insider Monkey

7 months ago

MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now

We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely
MLTX

Simply Wall St.

7 months ago

We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely

MLTX

MT Newswires

8 months ago

Goldman Sachs Upgrades MoonLake Immunotherapeutics to Buy From Neutral, Adjusts Price Target to $82 From $62

MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
MLTX

TipRanks

8 months ago

MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG

MLTX

MT Newswires

8 months ago

BTIG Adjusts MoonLake Immunotherapeutics' Price Target to $81 From $71, Keeps Buy Rating

MLTX

MT Newswires

8 months ago

MoonLake's Three New Trials Will Expand Sonelokimab's Potential, Wedbush Says

MLTX

MT Newswires

8 months ago

MoonLake Immunotherapeutics Starts Three New Clinical Trials Evaluating Sonelokimab in Inflammatory Diseases

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
MLTX

GlobeNewswire

8 months ago

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?
MLTX

Simply Wall St.

9 months ago

Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MLTX

GlobeNewswire

10 months ago

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

MLTX

MT Newswires

10 months ago

MoonLake Immunotherapeutics' Q3 Net Loss Widens

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
MLTX

GlobeNewswire

10 months ago

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

MLTX

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/09/2024

MLTX

GuruFocus.com

a year ago

Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics

MLTX

MT Newswires

a year ago

Moonlake Immunotherapeutics Insider Sold Shares Worth $9,186,120, According to a Recent SEC Filing

Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?
MLTX

Insider Monkey

a year ago

Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?

MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock
MLTX

Insider Monkey

a year ago

MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
MLTX

GlobeNewswire

a year ago

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics (MLTX): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
MLTX

Insider Monkey

a year ago

MoonLake Immunotherapeutics (MLTX): One of Oppenheimer’s Top Stock Picks For the Next 12 Months

MLTX

MT Newswires

a year ago

MoonLake Immunotherapeutics Shares Fall After Wolfe Research Downgrade

MLTX

MT Newswires

a year ago

Wolfe Research Downgrades MoonLake Immunotherapeutics to Peer Perform From Outperform

We're Interested To See How MoonLake Immunotherapeutics (NASDAQ:MLTX) Uses Its Cash Hoard To Grow
MLTX

Simply Wall St.

a year ago

We're Interested To See How MoonLake Immunotherapeutics (NASDAQ:MLTX) Uses Its Cash Hoard To Grow

MLTX

MT Newswires

a year ago

MoonLake Immunotherapeutics Shares Slightly Up Despite Wider Q2 Loss

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
MLTX

GlobeNewswire

a year ago

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MLTX

MT Newswires

a year ago

Oppenheimer Initiates MoonLake Immunotherapeutics at Outperform With $104 Price Target

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities
MLTX

GlobeNewswire

a year ago

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)
MLTX

Motley Fool

a year ago

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans
MLTX

CNW Group

a year ago

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike
MLTX

Investor's Business Daily

a year ago

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike

EPCOR and HAWSCo Enter Ownership Transfer Agreement
MLTX

CNW Group

a year ago

EPCOR and HAWSCo Enter Ownership Transfer Agreement

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate
MLTX

GlobeNewswire

a year ago

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate

Southwest Airlines stock pops on report of Elliott's $2B stake
MLTX

Yahoo Finance Video

a year ago

Southwest Airlines stock pops on report of Elliott's $2B stake

MLTX

Business Wire

a year ago

Form 8.3 - Virgin Money UK plc

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
MLTX

GlobeNewswire

a year ago

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MLTX

GlobeNewswire

a year ago

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MLTX

GuruFocus.com

a year ago

MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes

MLTX

MT Newswires

a year ago

MoonLake Immunotherapeutics Q1 Net Loss Widens

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MLTX

GlobeNewswire

a year ago

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
MLTX

Business Wire

a year ago

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
MLTX

Simply Wall St.

2 years ago

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
MLTX

Investor's Business Daily

2 years ago

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MLTX

GlobeNewswire

2 years ago

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MLTX

GlobeNewswire

2 years ago

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)
MLTX

GuruFocus.com

2 years ago

Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
MLTX

GlobeNewswire

2 years ago

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
MLTX

GlobeNewswire

2 years ago

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics
MLTX

GuruFocus.com

2 years ago

Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics

Beazer Homes (BZH) Q1 Earnings & Revenues Miss, Orders Up
MLTX

Zacks

2 years ago

Beazer Homes (BZH) Q1 Earnings & Revenues Miss, Orders Up

Zurn Elkay Water Solutions Declares Quarterly Cash Dividend
MLTX

Business Wire

2 years ago

Zurn Elkay Water Solutions Declares Quarterly Cash Dividend

Why Fast-paced Mover Celestica (CLS) Is a Great Choice for Value Investors
MLTX

Zacks

2 years ago

Why Fast-paced Mover Celestica (CLS) Is a Great Choice for Value Investors

Noble Corporation plc announces changes to its share capital for the month of January 2024
MLTX

PR Newswire

2 years ago

Noble Corporation plc announces changes to its share capital for the month of January 2024

Rush Enterprises, Inc. Conference Call Advisory for Fourth Quarter and Year-End 2023 Earnings Results
MLTX

GlobeNewswire

2 years ago

Rush Enterprises, Inc. Conference Call Advisory for Fourth Quarter and Year-End 2023 Earnings Results

MLTX

Argus Research

2 years ago

Daily – Vickers Top Buyers & Sellers for 01/31/2024

Director John Schultz Acquires 8,559 Shares of Columbia Banking System Inc
MLTX

GuruFocus.com

2 years ago

Director John Schultz Acquires 8,559 Shares of Columbia Banking System Inc

Is Janus Henderson Enterprise I (JMGRX) a Strong Mutual Fund Pick Right Now?
MLTX

Zacks

2 years ago

Is Janus Henderson Enterprise I (JMGRX) a Strong Mutual Fund Pick Right Now?

VNT vs. VLTO: Which Stock Should Value Investors Buy Now?
MLTX

Zacks

2 years ago

VNT vs. VLTO: Which Stock Should Value Investors Buy Now?

A Motley Fool Co-Founder's Roller-Coaster Nvidia Story
MLTX

Motley Fool

2 years ago

A Motley Fool Co-Founder's Roller-Coaster Nvidia Story

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis
MLTX

GlobeNewswire

2 years ago

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

3 Asset Management Stocks Set to Pull Off Earnings Beat in Q4
MLTX

Zacks

2 years ago

3 Asset Management Stocks Set to Pull Off Earnings Beat in Q4

Novo Nordisk Puts Pharma Peers in the Shade as Key Earnings Reports Awaited
MLTX

Bloomberg

2 years ago

Novo Nordisk Puts Pharma Peers in the Shade as Key Earnings Reports Awaited

MAG Silver (MAG) Reports Solid Production at Juanicipio
MLTX

Zacks

2 years ago

MAG Silver (MAG) Reports Solid Production at Juanicipio

19 Best Reusable Water Bottles on Amazon Under $50
MLTX

Insider Monkey

2 years ago

19 Best Reusable Water Bottles on Amazon Under $50

Are You Looking for a High-Growth Dividend Stock?
MLTX

Zacks

2 years ago

Are You Looking for a High-Growth Dividend Stock?

MLTX

Business Wire

2 years ago

Webster Financial Corporation Declares Common and Preferred Dividends

Here's Why Transocean (RIG) Fell More Than Broader Market
MLTX

Zacks

2 years ago

Here's Why Transocean (RIG) Fell More Than Broader Market

Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now
MLTX

Zacks

2 years ago

Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now

Colliers to announce fourth quarter and full year results on February 8, 2024
MLTX

GlobeNewswire

2 years ago

Colliers to announce fourth quarter and full year results on February 8, 2024

Cytokinetics Stock Drops After Journal Report That Novartis Deal Might Be Off
MLTX

The Wall Street Journal

2 years ago

Cytokinetics Stock Drops After Journal Report That Novartis Deal Might Be Off

Share on Social Networks: